MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Penumbra Long-Term Debt 2011-2026 | PEN
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Penumbra
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.7 M | 23.7 M | 24.9 M | 26.5 M | 44.2 M | - | - | - | - | - | - | 6 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.2 M | 6 M | 24.5 M |
Quarterly Long-Term Debt Penumbra
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.2 M | 21.8 M | 21.2 M | 22.2 M | 22.5 M | 23.1 M | 23.8 M | 23.9 M | 24.4 M | 24.9 M | 25.3 M | - | 26.1 M | 26.5 M | 26.8 M | 51.9 M | 27 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 26.7 M | 26.7 M | 26.7 M | 26.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 51.9 M | 21.2 M | 26.2 M |
Long-Term Debt of other stocks in the Medical devices industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
47.5 M | $ 33.22 | 1.87 % | $ 1.47 B |  USA |
 |
Allied Healthcare Products
AHPI
|
2.93 K | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
34 M | - | - | $ 475 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
71.3 M | - | - | $ 1.77 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
7.56 M | - | - | $ 3.31 B | USA |
 |
Acutus Medical
AFIB
|
32.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
430 K | - | -5.86 % | $ 30.6 M | USA |
 |
Aziyo Biologics
AZYO
|
20.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
24.1 M | $ 7.01 | 2.04 % | $ 503 M |  Israel |
 |
Apyx Medical Corporation
APYX
|
33.2 M | $ 3.76 | -1.7 % | $ 130 M | USA |
 |
Alphatec Holdings
ATEC
|
575 M | $ 13.29 | 1.41 % | $ 1.9 B | USA |
 |
BIOLASE
BIOL
|
11.8 M | - | -13.19 % | $ 166 K | USA |
 |
Bio-Rad Laboratories
BIO
|
1.2 B | $ 255.19 | -12.51 % | $ 7.2 B | USA |
 |
Conformis
CFMS
|
20.6 M | - | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
2.06 B | $ 36.35 | -3.09 % | $ 5.42 K | USA |
 |
BioSig Technologies
BSGM
|
103 K | - | 37.08 % | $ 85.7 M | USA |
 |
CONMED Corporation
CNMD
|
905 M | $ 41.59 | -0.28 % | $ 1.28 B | USA |
 |
Boston Scientific Corporation
BSX
|
8.97 B | $ 74.77 | 0.88 % | $ 110 B | USA |
 |
Abbott Laboratories
ABT
|
12.6 B | $ 112.22 | 0.66 % | $ 195 B | USA |
 |
Cardiovascular Systems
CSII
|
1.33 M | - | 0.15 % | $ 844 M | USA |
 |
EDAP TMS S.A.
EDAP
|
2.16 M | $ 4.8 | 0.63 % | $ 179 M |  France |
 |
Delcath Systems
DCTH
|
10.2 M | $ 9.25 | 1.43 % | $ 264 M | USA |
 |
Cutera
CUTR
|
1.06 M | - | -10.19 % | $ 1.99 M | USA |
 |
CryoLife, Inc.
CRY
|
290 M | - | -4.14 % | $ 702 M | USA |
 |
ClearPoint Neuro
CLPT
|
3.01 M | $ 13.44 | 3.07 % | $ 363 M | USA |
 |
Electromed
ELMD
|
1.1 M | $ 24.2 | 3.82 % | $ 205 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
154 K | - | 0.03 % | $ 1.58 B | Israel |
 |
Dynatronics Corporation
DYNT
|
1.11 M | - | 14.99 % | $ 929 K | USA |
 |
Misonix, Inc.
MSON
|
38.6 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
7.64 M | - | - | $ 111 M |  Canada |
 |
Intersect ENT, Inc.
XENT
|
63.6 M | - | - | $ 955 M | USA |
 |
Eargo
EAR
|
11.9 M | - | - | $ 10.2 M | USA |
 |
Inogen
INGN
|
16.6 M | $ 5.71 | -1.38 % | $ 135 M | USA |
 |
IRadimed Corporation
IRMD
|
1.42 K | $ 99.81 | -0.03 % | $ 1.26 B | USA |
 |
GBS
GBS
|
1.65 M | - | -0.57 % | $ 7.12 M | USA |
 |
Integer Holdings Corporation
ITGR
|
980 M | $ 85.46 | 0.23 % | $ 2.87 B | USA |
 |
Second Sight Medical Products
EYES
|
18 M | - | -0.97 % | $ 54.4 M | USA |
 |
Avinger
AVGR
|
1.1 M | - | -20.74 % | $ 369 K | USA |
 |
FONAR Corporation
FONR
|
155 K | $ 18.55 | 0.05 % | $ 122 M | USA |
 |
Pulmonx Corporation
LUNG
|
34 M | $ 1.47 | 3.17 % | $ 57.5 M | USA |
 |
Globus Medical
GMED
|
298 K | $ 87.89 | 0.76 % | $ 11.9 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
760 M | $ 11.29 | 4.46 % | $ 869 M | USA |
 |
Myomo
MYO
|
200 K | $ 0.82 | 0.41 % | $ 5.78 M | USA |
 |
Establishment Labs Holdings
ESTA
|
220 M | $ 75.22 | 2.28 % | $ 2.12 B |  Costa-rica |